LOXL2 and non-small cell lung carcinoma: In patients with non-small cell lung cancer (NSCLC), the expression levels of PLOD1–3 and LOXL2—genes involved in collagen crosslinking—are significantly elevated in TECs compared to normal endothelial cells.